Severe thrombocytopenia in covid-19: A conundrum in dengue-endemic areas

2Citations
Citations of this article
49Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Thrombocytopenia in COVID-19 can be attributed to multiple factors. Most often it is disease related. It is usually mild and if severe often associated with severe COVID-19 disease. It can also be due to drugs (Remdesivir, Tocilizumab) or coinfection with other viruses. Here we report two cases of severe thrombocytopenia in COVID-19 due to dengue coinfection. Most often the thrombocytopenia in dengue is self-resolving, and a careful “wait and watch” should suffice unlike COVID-19, where steroids can help if the cytopenia is due to cytokine storm or immune-mediated effects.

Author supplied keywords

Cite

CITATION STYLE

APA

Adarsh, M. B., Abraham, A., Kavitha, P., Nandakumar, M. M., & Vaman, R. S. (2021). Severe thrombocytopenia in covid-19: A conundrum in dengue-endemic areas. Indian Journal of Critical Care Medicine, 25(4), 465–466. https://doi.org/10.5005/jp-journals-10071-23778

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free